好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Obesity, In-hospital Outcomes, and Disparities in Myasthenia Gravis Exacerbation: A Nationwide Analysis
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (8:00 AM-9:00 AM)
9-016
To investigate the association of obesity with inpatient outcomes in myasthenia gravis exacerbation and crisis using the national inpatient sample database for the years 2016-2022.
Studies have shown that myasthenia gravis and obesity are associated. However, data of class-specific associations and outcomes are limited.
We identified myasthenia gravis (G700*) and obesity (E66) using ICD-10 codes, with obesity stratified by BMI (Class I: 30–34.9, II: 35–39.9, III: ≥40). Outcomes during myasthenia gravis exacerbation hospitalization were measured such as mortality, discharge home, length of stay, and cost, use of  plasmapheresis. We used survey-weighted multivariate regression, adjusting for demographics, comorbidity index, and APR-DRG severity, with statistical significance at p<0.05.
Of ~300,000 Myasthenia Gravis (MG) hospitalizations, 64,965 were for MG exacerbation (mean age 62.8 years), with 23.8% obesity prevalence. In the exacerbation cohort, Class II obesity was associated with 52% lower in-hospital mortality (aOR 0.48, 95% CI 0.26–0.88), with an adjusted mortality rate of 2.17% versus 4.34% in non-obese patients. Patients with Class I (aOR 1.20) and Class II obesity (aOR 1.30) had higher odds of being discharged home. In contrast, Class III obesity was linked to an 8% longer length of stay (LOS) (IRR 1.08). Mortality risk increased with age (aOR 1.073 per year) and comorbidity score (aOR 1.175 per point). While obesity did not increase hospital charges, significant racial disparities were observed. Compared to White patients, Black patients had 28% lower odds of home discharge (aOR 0.72, p<0.001) and a 13% longer LOS (IRR 1.13, p<0.001). Total hospital charges were substantially higher for Hispanic ($109,509) and Asian ($114,987) patients versus White patients ($86,964, p<0.001).
In MG exacerbation hospitalization
Authors/Disclosures
Hafiz M. Maaz (Quaid-e-Azam Medical College, Bahawalpur Pakistan)
PRESENTER
Mr. Maaz has nothing to disclose.
Muhammad Sohaib, MBBS Mr. Sohaib has nothing to disclose.
Muhammad Tayyab Muzaffar Chaychi, MD Muhammad Tayyab Muzaffar Chaychi, MD has nothing to disclose.
Rawdah Shakil, MBBS Ms. Shakil has nothing to disclose.
Muhammad Ahmed, MD (Medical College of Georgia, Augusta University) Dr. Ahmed has nothing to disclose.
Haris Kamal, MD (University of Texas At Houston) Dr. Kamal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention .